Autonomic	B:C1837624
,	O
functional	O
,	O
skeletal	O
muscle	I:C0302142
,	O
and	O
cardiac	O
abnormalities	I:C0018798
are	O
associated	O
with	O
increased	O
ergoreflex	O
sensitivity	I:C0243095
in	O
mitochondrial	O
disease	I:C0751651
.	O

Autonomic	O
,	O
functional	B:C0302142
,	O
skeletal	O
muscle	I:C0302142
,	O
and	O
cardiac	O
abnormalities	I:C0018798
are	O
associated	O
with	O
increased	O
ergoreflex	O
sensitivity	I:C0243095
in	O
mitochondrial	O
disease	I:C0751651
.	O

Autonomic	O
,	O
functional	O
,	O
skeletal	B:C0302142
muscle	I:C0302142
,	O
and	O
cardiac	O
abnormalities	I:C0018798
are	O
associated	O
with	O
increased	O
ergoreflex	O
sensitivity	I:C0243095
in	O
mitochondrial	O
disease	I:C0751651
.	O

Autonomic	O
,	O
functional	O
,	O
skeletal	O
muscle	I:C0302142
,	O
and	O
cardiac	B:C0018798
abnormalities	I:C0018798
are	O
associated	O
with	O
increased	O
ergoreflex	O
sensitivity	I:C0243095
in	O
mitochondrial	O
disease	I:C0751651
.	O

Autonomic	O
,	O
functional	O
,	O
skeletal	O
muscle	I:C0302142
,	O
and	O
cardiac	O
abnormalities	I:C0018798
are	O
associated	O
with	O
increased	O
ergoreflex	B:C0243095
sensitivity	I:C0243095
in	O
mitochondrial	O
disease	I:C0751651
.	O

Autonomic	O
,	O
functional	O
,	O
skeletal	O
muscle	I:C0302142
,	O
and	O
cardiac	O
abnormalities	I:C0018798
are	O
associated	O
with	O
increased	O
ergoreflex	O
sensitivity	I:C0243095
in	O
mitochondrial	B:C0751651
disease	I:C0751651
.	O

Mitochondrial	B:C0751651
disease	I:C0751651
(	O
Mitochondrial	O
disease	I:C0751651
)	O
is	O
a	O
genetic	O
disorder	I:C0019247
affecting	O
skeletal	O
muscles	I:C0242692
,	O
with	O
possible	O
myocardial	O
disease	I:C0878544
.	O

Mitochondrial	O
disease	I:C0751651
(	O
Mitochondrial	B:C0751651
disease	I:C0751651
)	O
is	O
a	O
genetic	O
disorder	I:C0019247
affecting	O
skeletal	O
muscles	I:C0242692
,	O
with	O
possible	O
myocardial	O
disease	I:C0878544
.	O

Mitochondrial	O
disease	I:C0751651
(	O
Mitochondrial	O
disease	I:C0751651
)	O
is	O
a	O
genetic	B:C0019247
disorder	I:C0019247
affecting	O
skeletal	O
muscles	I:C0242692
,	O
with	O
possible	O
myocardial	O
disease	I:C0878544
.	O

Mitochondrial	O
disease	I:C0751651
(	O
Mitochondrial	O
disease	I:C0751651
)	O
is	O
a	O
genetic	O
disorder	I:C0019247
affecting	O
skeletal	B:C0242692
muscles	I:C0242692
,	O
with	O
possible	O
myocardial	O
disease	I:C0878544
.	O

Mitochondrial	O
disease	I:C0751651
(	O
Mitochondrial	O
disease	I:C0751651
)	O
is	O
a	O
genetic	O
disorder	I:C0019247
affecting	O
skeletal	O
muscles	I:C0242692
,	O
with	O
possible	O
myocardial	B:C0878544
disease	I:C0878544
.	O

The	O
ergoreflex	B:C0034929
,	O
sensitive	O
to	O
skeletal	O
muscle	I:C0242692
work	O
,	O
regulates	O
ventilatory	O
and	O
autonomic	O
responses	O
to	O
exercise	O
.	O

The	O
ergoreflex	O
,	O
sensitive	O
to	O
skeletal	B:C0242692
muscle	I:C0242692
work	O
,	O
regulates	O
ventilatory	O
and	O
autonomic	O
responses	O
to	O
exercise	O
.	O

The	O
ergoreflex	O
,	O
sensitive	O
to	O
skeletal	O
muscle	I:C0242692
work	O
,	O
regulates	B:C1327622
ventilatory	O
and	O
autonomic	O
responses	O
to	O
exercise	O
.	O

The	O
ergoreflex	O
,	O
sensitive	O
to	O
skeletal	O
muscle	I:C0242692
work	O
,	O
regulates	O
ventilatory	B:C1321070
and	O
autonomic	O
responses	O
to	O
exercise	O
.	O

We	O
hypothesized	O
the	O
presence	O
of	O
an	O
increased	O
ergoreflex	B:C0243095
sensitivity	I:C0243095
in	O
Mitochondrial	O
disease	I:C0751651
patients	O
,	O
its	O
association	O
with	O
abnormal	O
ventilatory	O
and	O
autonomic	O
responses	O
,	O
and	O
possibly	O
with	O
subclinical	O
cardiac	I:C0243095
involvement	I:C0243095
.	O

We	O
hypothesized	O
the	O
presence	O
of	O
an	O
increased	O
ergoreflex	O
sensitivity	I:C0243095
in	O
Mitochondrial	B:C0751651
disease	I:C0751651
patients	O
,	O
its	O
association	O
with	O
abnormal	O
ventilatory	O
and	O
autonomic	O
responses	O
,	O
and	O
possibly	O
with	O
subclinical	O
cardiac	I:C0243095
involvement	I:C0243095
.	O

We	O
hypothesized	O
the	O
presence	O
of	O
an	O
increased	O
ergoreflex	O
sensitivity	I:C0243095
in	O
Mitochondrial	O
disease	I:C0751651
patients	O
,	O
its	O
association	O
with	O
abnormal	B:C0205161
ventilatory	O
and	O
autonomic	O
responses	O
,	O
and	O
possibly	O
with	O
subclinical	O
cardiac	I:C0243095
involvement	I:C0243095
.	O

We	O
hypothesized	O
the	O
presence	O
of	O
an	O
increased	O
ergoreflex	O
sensitivity	I:C0243095
in	O
Mitochondrial	O
disease	I:C0751651
patients	O
,	O
its	O
association	O
with	O
abnormal	O
ventilatory	B:C1321070
and	O
autonomic	O
responses	O
,	O
and	O
possibly	O
with	O
subclinical	O
cardiac	I:C0243095
involvement	I:C0243095
.	O

We	O
hypothesized	O
the	O
presence	O
of	O
an	O
increased	O
ergoreflex	O
sensitivity	I:C0243095
in	O
Mitochondrial	O
disease	I:C0751651
patients	O
,	O
its	O
association	O
with	O
abnormal	O
ventilatory	O
and	O
autonomic	O
responses	O
,	O
and	O
possibly	O
with	O
subclinical	B:C0243095
cardiac	I:C0243095
involvement	I:C0243095
.	O

Twenty	O
-	O
five	O
Mitochondrial	B:C0751651
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	B:C0025266
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	B:C1533847
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	B:C0018799
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	B:C0220825
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	B:C1095989
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	B:C3496493
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	B:C0201782
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	B:C0007621
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	B:C0201782
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	B:C0523952
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	B:C0546632
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	B:C0013798
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	B:C0013798
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	B:C2959886
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	B:C0013516
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	B:C0024485
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	B:C0024485
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	O
assessment	I:C0220825
.	O

Twenty	O
-	O
five	O
Mitochondrial	O
disease	I:C0751651
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	I:C1533847
but	O
without	O
known	O
cardiac	O
disease	I:C0018799
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	O
,	O
galectin	O
-	I:C3496493
3	I:C3496493
,	O
soluble	O
suppression	I:C0201782
of	O
tumorigenesis	O
2	I:C0007621
(	O
soluble	O
suppression	I:C0201782
of	I:C0201782
tumorigenesis	I:C0201782
2	I:C0201782
)	O
,	O
high	O
sensitivity	O
troponin	O
T/I	I:C0523952
,	O
catecholamines	O
,	O
ECG	O
,	O
24-h	O
ECG	I:C0013798
recording	I:C0013798
,	O
cardiopulmonary	O
exercise	I:C2959886
testing	I:C2959886
,	O
echocardiography	O
,	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
(	O
cardiac	O
/	I:C0024485
muscle	I:C0024485
magnetic	I:C0024485
resonance	I:C0024485
)	O
,	O
and	O
ergoreflex	B:C0220825
assessment	I:C0220825
.	O

Among	O
these	O
myopathic	B:C0026848
patients	O
,	O
subclinical	O
cardiac	I:C0243095
damage	I:C0243095
was	O
detected	O
in	O
up	O
to	O
80	O
%	O
,	O
with	O
44	O
%	O
showing	O
fibrosis	O
at	O
CMR	O
.	O

Among	O
these	O
myopathic	O
patients	O
,	O
subclinical	B:C0243095
cardiac	I:C0243095
damage	I:C0243095
was	O
detected	O
in	O
up	O
to	O
80	O
%	O
,	O
with	O
44	O
%	O
showing	O
fibrosis	O
at	O
CMR	O
.	O

Among	O
these	O
myopathic	O
patients	O
,	O
subclinical	O
cardiac	I:C0243095
damage	I:C0243095
was	O
detected	B:C0442726
in	O
up	O
to	O
80	O
%	O
,	O
with	O
44	O
%	O
showing	O
fibrosis	O
at	O
CMR	O
.	O

Among	O
these	O
myopathic	O
patients	O
,	O
subclinical	O
cardiac	I:C0243095
damage	I:C0243095
was	O
detected	O
in	O
up	O
to	O
80	O
%	O
,	O
with	O
44	O
%	O
showing	O
fibrosis	B:C0016059
at	O
CMR	O
.	O

Among	O
these	O
myopathic	O
patients	O
,	O
subclinical	O
cardiac	I:C0243095
damage	I:C0243095
was	O
detected	O
in	O
up	O
to	O
80	O
%	O
,	O
with	O
44	O
%	O
showing	O
fibrosis	O
at	O
CMR	B:C0024485
.	O

Ergoreflex	B:C0243095
sensitivity	I:C0243095
was	O
markedly	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
64	O
%	O
vs.	O
37	O
%	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
correlated	O
with	O
muscle	O
fat	O
to	O
water	O
ratio	O
and	O
extracellular	O
volume	O
at	O
MMR	O
(	O
both	O
P	O
<	O
0.05	O
)	O
.	O

Ergoreflex	O
sensitivity	I:C0243095
was	O
markedly	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
64	O
%	O
vs.	O
37	O
%	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
correlated	O
with	O
muscle	O
fat	O
to	O
water	O
ratio	O
and	O
extracellular	B:C0521119
volume	O
at	O
MMR	O
(	O
both	O
P	O
<	O
0.05	O
)	O
.	O

Ergoreflex	O
sensitivity	I:C0243095
was	O
markedly	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
64	O
%	O
vs.	O
37	O
%	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
correlated	O
with	O
muscle	O
fat	O
to	O
water	O
ratio	O
and	O
extracellular	O
volume	O
at	O
MMR	B:C0024485
(	O
both	O
P	O
<	O
0.05	O
)	O
.	O

Among	O
patients	O
,	O
ergoreflex	B:C0243095
sensitivity	I:C0243095
was	O
higher	O
in	O
those	O
with	O
cardiac	O
involvement	I:C0243095
(	O
P	O
=	O
0.034	O
)	O
.	O

Among	O
patients	O
,	O
ergoreflex	O
sensitivity	I:C0243095
was	O
higher	O
in	O
those	O
with	O
cardiac	B:C0243095
involvement	I:C0243095
(	O
P	O
=	O
0.034	O
)	O
.	O

Patients	O
showed	O
a	O
lower	O
peak	O
oxygen	B:C0030055
consumption	I:C0030055
(	O
VO2	O
/	O
kg	O
)	O
than	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
,	O
as	O
well	O
as	O
ventilatory	O
inefficiency	I:C3540840
(	O
P	O
=	O
0.024	O
)	O
.	O

Patients	O
showed	O
a	O
lower	O
peak	O
oxygen	O
consumption	I:C0030055
(	O
VO2	B:C0030055
/	O
kg	O
)	O
than	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
,	O
as	O
well	O
as	O
ventilatory	O
inefficiency	I:C3540840
(	O
P	O
=	O
0.024	O
)	O
.	O

Patients	O
showed	O
a	O
lower	O
peak	O
oxygen	O
consumption	I:C0030055
(	O
VO2	O
/	O
kg	O
)	O
than	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
,	O
as	O
well	O
as	O
ventilatory	B:C3540840
inefficiency	I:C3540840
(	O
P	O
=	O
0.024	O
)	O
.	O

Ergoreflex	B:C0243095
sensitivity	I:C0243095
correlated	O
with	O
reduced	O
workload	O
and	O
peak	O
VO2	O
/	O
kg	O
(	O
both	O
P	O
<	O
0.001	O
)	O
,	O
and	O
several	O
indicators	O
of	O
autonomic	O
imbalance	I:C0262385
(	O
P	O
<	O
0.05	O
)	O
.	O

Ergoreflex	O
sensitivity	I:C0243095
correlated	O
with	O
reduced	O
workload	O
and	O
peak	O
VO2	B:C0030055
/	O
kg	O
(	O
both	O
P	O
<	O
0.001	O
)	O
,	O
and	O
several	O
indicators	O
of	O
autonomic	O
imbalance	I:C0262385
(	O
P	O
<	O
0.05	O
)	O
.	O

Ergoreflex	O
sensitivity	I:C0243095
correlated	O
with	O
reduced	O
workload	O
and	O
peak	O
VO2	O
/	O
kg	O
(	O
both	O
P	O
<	O
0.001	O
)	O
,	O
and	O
several	O
indicators	O
of	O
autonomic	B:C0262385
imbalance	I:C0262385
(	O
P	O
<	O
0.05	O
)	O
.	O

Plasma	B:C0032105
norepinephrine	O
was	O
the	O
unique	O
predictor	O
of	O
myocardial	O
fibrosis	I:C0151654
at	O
univariate	O
analysis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Plasma	O
norepinephrine	B:C0028351
was	O
the	O
unique	O
predictor	O
of	O
myocardial	O
fibrosis	I:C0151654
at	O
univariate	O
analysis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Plasma	O
norepinephrine	O
was	O
the	O
unique	O
predictor	O
of	O
myocardial	B:C0151654
fibrosis	I:C0151654
at	O
univariate	O
analysis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Skeletal	B:C1533847
myopathy	I:C1533847
in	O
Mitochondrial	O
disease	I:C0751651
is	O
characterized	O
by	O
enhanced	O
ergoreflex	O
sensitivity	I:C0243095
,	O
which	O
is	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
cardiac	O
involvement	I:C0243095
,	O
exercise	O
intolerance	I:C0424551
,	O
and	O
sympathetic	O
activation	O
.	O

Skeletal	O
myopathy	I:C1533847
in	O
Mitochondrial	B:C0751651
disease	I:C0751651
is	O
characterized	O
by	O
enhanced	O
ergoreflex	O
sensitivity	I:C0243095
,	O
which	O
is	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
cardiac	O
involvement	I:C0243095
,	O
exercise	O
intolerance	I:C0424551
,	O
and	O
sympathetic	O
activation	O
.	O

Skeletal	O
myopathy	I:C1533847
in	O
Mitochondrial	O
disease	I:C0751651
is	O
characterized	O
by	O
enhanced	O
ergoreflex	B:C0243095
sensitivity	I:C0243095
,	O
which	O
is	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
cardiac	O
involvement	I:C0243095
,	O
exercise	O
intolerance	I:C0424551
,	O
and	O
sympathetic	O
activation	O
.	O

Skeletal	O
myopathy	I:C1533847
in	O
Mitochondrial	O
disease	I:C0751651
is	O
characterized	O
by	O
enhanced	O
ergoreflex	O
sensitivity	I:C0243095
,	O
which	O
is	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
cardiac	B:C0243095
involvement	I:C0243095
,	O
exercise	O
intolerance	I:C0424551
,	O
and	O
sympathetic	O
activation	O
.	O

Skeletal	O
myopathy	I:C1533847
in	O
Mitochondrial	O
disease	I:C0751651
is	O
characterized	O
by	O
enhanced	O
ergoreflex	O
sensitivity	I:C0243095
,	O
which	O
is	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
cardiac	O
involvement	I:C0243095
,	O
exercise	B:C0424551
intolerance	I:C0424551
,	O
and	O
sympathetic	O
activation	O
.	O

